Search
Search Results
-
FXR activation remodels hepatic and intestinal transcriptional landscapes in metabolic dysfunction-associated steatohepatitis
The escalating obesity epidemic and aging population have propelled metabolic dysfunction-associated steatohepatitis (MASH) to the forefront of...
-
ACLY as a modulator of liver cell functions and its role in Metabolic Dysfunction-Associated Steatohepatitis
BackgroundNon-alcoholic Fatty Liver Disease (NAFLD), now better known as Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD) and its...
-
Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA+ B cells
BackgroundDysregulation of immune surveillance is tightly linked to the development of metabolic dysfunction-associated steatohepatitis (MASH)-driven...
-
Phenotypic and metabolomic characteristics of mouse models of metabolic associated steatohepatitis
BackgroundMetabolic associated steatohepatitis (MASH) is metabolic disease that may progress to cirrhosis and hepatocellular carcinoma. Mouse models...
-
The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies
BackgroundObesity, characterized by visceral adipose tissue (VAT) expansion, is closely associated with metabolic dysfunction-associated steatotic...
-
Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice
BackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in Western countries, evolving into metabolic...
-
Impacts of liver macrophages, gut microbiota, and bile acid metabolism on the differences in iHFC diet-induced MASH progression between TSNO and TSOD mice
BackgroundTsumura-Suzuki non-obese (TSNO) mice exhibit a severe form of metabolic dysfunction-associated steatohepatitis (MASH) with advanced liver...
-
Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic liver disease that can progress to end-stage...
-
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors. A 48-week...
-
An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the commonest cause of chronic liver disease worldwide and represents an unmet...
-
Heterocyclic Amines Disrupt Lipid Homeostasis in Cryopreserved Human Hepatocytes
Metabolic dysfunction associated-steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) is the liver manifestation...
-
-
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
BackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is estimated to affect 30% of the world’s population, and its prevalence...
-
Abnormal protein SUMOylation in liver disease: novel target for therapy
SUMOylation is an important protein post-translational modification (PTM) process, in which the small ubiquitin-like modifier (SUMO) protein...
-
Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment
Liver disease is a significant health burden globally and accounts for 4% of total deaths annually. Alcoholic liver disease (ALD) and...
-
Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis
ObjectivePrevious studies reported that pirfenidone (PFD) is associated with liver disease. However, the effects of pirfenidone on energy metabolism...
